BioArctic (OM:BIOA B) - Aandelenkoers, Nieuws & Analyse

BIOA B Overzicht aandelen

BioArctic AB (publ) ontwikkelt biologische geneesmiddelen voor patiënten met aandoeningen van het centrale zenuwstelsel in Zweden. Meer informatie

BIOA B fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	6/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Verhandeld tegen 46.9% onder onze schatting van de reële waarde

De winst zal naar verwachting met 62.46% per jaar groeien

Analisten zijn het erover eens dat de aandelenkoers met 69.2% zal stijgen

Risicoanalyse

Volatiele aandelenkoers in de afgelopen 3 maanden

BioArctic AB (publ) Concurrenten

Bonesupport Holding

OM:BONEX

SEK 23.7b

BioGaia

OM:BIOG B

SEK 10.7b

Vitrolife

OM:VITR

SEK 30.0b

Swedish Orphan Biovitrum

OM:SOBI

SEK 99.6b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor BioArctic
Historische aandelenkoersen
Huidige aandelenkoers	SEK 189.60
52 Week Hoogtepunt	SEK 288.40
52 Week Laag	SEK 137.70
Bèta	-0.25
11 maand verandering	20.15%
3 maanden verandering	17.54%
1 Jaar Verandering	-19.32%
33 jaar verandering	60.41%
5 jaar verandering	105.75%
Verandering sinds IPO	553.79%

Recent nieuws en updates

Recent updates

BioArctic AB (publ) (STO:BIOA B) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Sep 01

Need To Know: The Consensus Just Cut Its BioArctic AB (publ) (STO:BIOA B) Estimates For 2024

Aug 15

Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)

Apr 13

News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat

Feb 19

News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat

Feb 03

Investors Interested In BioArctic AB (publ)'s (STO:BIOA B) Revenues

Dec 23

With EPS Growth And More, BioArctic (STO:BIOA B) Makes An Interesting Case

Nov 12

BioArctic AB (publ) (STO:BIOA B) Analysts Are Way More Bearish Than They Used To Be

Jul 21

Analysts Have Lowered Expectations For BioArctic AB (publ) (STO:BIOA B) After Its Latest Results

Jul 15

New Forecasts: Here's What Analysts Think The Future Holds For BioArctic AB (publ) (STO:BIOA B)

Jul 07

Things Look Grim For BioArctic AB (publ) (STO:BIOA B) After Today's Downgrade

May 06

Companies Like BioArctic (STO:BIOA B) Can Afford To Invest In Growth

Mar 13

Broker Revenue Forecasts For BioArctic AB (publ) (STO:BIOA B) Are Surging Higher

Nov 30

We're Not Worried About BioArctic's (STO:BIOA B) Cash Burn

Sep 16

We're Interested To See How BioArctic (STO:BIOA B) Uses Its Cash Hoard To Grow

Apr 04

Rendement voor aandeelhouders

	BIOA B	SE Biotechs	SE Markt
7D	6.0%	-0.5%	-0.2%
1Y	-19.3%	14.3%	11.8%

Rendement versus industrie: BIOA B presteerde slechter dan de Swedish Biotechs -sector, die het afgelopen jaar een rendement van 14.3 % opleverde.

Rendement versus markt: BIOA B presteerde slechter dan Swedish Market, dat het afgelopen jaar een rendement van 11.8 % opleverde.

Prijsvolatiliteit

Is BIOA B's price volatile compared to industry and market?
BIOA B volatility
BIOA B Average Weekly Movement	10.9%
Biotechs Industry Average Movement	9.3%
Market Average Movement	5.5%
10% most volatile stocks in SE Market	11.2%
10% least volatile stocks in SE Market	3.3%

Stabiele aandelenkoers: De aandelenkoers van BIOA B is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 11% ) van BIOA B is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen Swedish.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2000	104	Gunilla Osswald	www.bioarctic.se

BioArctic AB (publ) ontwikkelt biologische geneesmiddelen voor patiënten met aandoeningen van het centrale zenuwstelsel in Zweden. Het bedrijf ontwikkelt Lecanemab, Lecanemab AHEAD 3-45 en Lecanemab Back-up voor de behandeling van de ziekte van Alzheimer. Daarnaast ontwikkelt het bedrijf AD-BT2802 en AD-BT2803 geneesmiddelenprojecten tegen de ziekte van Alzheimer die worden gecombineerd met bloed-hersenbarrièretechnologie en Brain Transporter om de opname van antilichamen in de hersenen te bevorderen.

BioArctic AB (publ) Samenvatting

Hoe verhouden de winst en inkomsten van BioArctic zich tot de beurswaarde?
BIOA B fundamentele statistieken
Marktkapitalisatie	SEK 16.76b
Inkomsten(TTM)	-SEK 232.86m
Inkomsten(TTM)	SEK 167.14m

100.2x

P/S-verhouding

-72.0x

Koers/Winstverhouding

Is BIOA B overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
BIOA B resultatenrekening (TTM)
Inkomsten	SEK 167.14m
Kosten van inkomsten	SEK 90.50m
Brutowinst	SEK 76.64m
Overige uitgaven	SEK 309.50m
Inkomsten	-SEK 232.86m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

Feb 13, 2025

Winst per aandeel (EPS)	-2.63
Brutomarge	45.85%
Nettowinstmarge	-139.32%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde BIOA B op de lange termijn?

Bekijk historische prestaties en vergelijking

BIOA B Overzicht aandelen

Beloningen

Risicoanalyse

BioArctic AB (publ) Concurrenten

OM:BONEX

SEK 23.7b

OM:BIOG B

SEK 10.7b

OM:VITR

SEK 30.0b

OM:SOBI

SEK 99.6b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Price target increased by 9.8% to kr321

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Eisai Co., Ltd. and BioAge Labs, Inc. Announce CHMP Issues Positive Recommendation for Approval of Lecanemab in the EU

BioArctic AB (publ) to Report Q2, 2025 Results on Aug 28, 2025

BioArctic AB (publ) Presents Nomination Committee

BioArctic AB (publ), Annual General Meeting, May 22, 2025

Recent updates

Price target increased by 9.8% to kr321

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Eisai Co., Ltd. and BioAge Labs, Inc. Announce CHMP Issues Positive Recommendation for Approval of Lecanemab in the EU

BioArctic AB (publ) to Report Q2, 2025 Results on Aug 28, 2025

BioArctic AB (publ) Presents Nomination Committee

BioArctic AB (publ), Annual General Meeting, May 22, 2025

Vice President of Human Resources exercised options and sold kr454k worth of stock

BioArctic AB (publ) (STO:BIOA B) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Price target decreased by 9.3% to kr291

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

BioArctic AB (publ) Announces Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology

Need To Know: The Consensus Just Cut Its BioArctic AB (publ) (STO:BIOA B) Estimates For 2024

Price target decreased by 8.6% to kr336

New major risk - Share price stability

Insufficient new directors

Insider recently sold kr710k worth of stock

BioArctic AB (publ) Approves Leqembi [®] for the Treatment of Alzheimer's Disease in South Korea

First quarter 2024 earnings: Revenues exceed analyst expectations

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)

BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Consensus EPS estimates increase by 112%

Vice President of Human Resources exercised options to buy kr1.2m worth of stock.

News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates fall by 15%

News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat

The European Medicines Agency's Scientific Advisory Group (SAG) to Discuss the Marketing Authorisation Application for lecanemab

Investors Interested In BioArctic AB (publ)'s (STO:BIOA B) Revenues

Consensus revenue estimates fall by 16%

Consensus revenue estimates fall by 14%

With EPS Growth And More, BioArctic (STO:BIOA B) Makes An Interesting Case

Independent Chairman recently bought kr1.1m worth of stock

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

BioArctic AB's (publ) Presents New Data on the Investigational Subcutaneous Formulation of LEQEMBI

VP & Head of Research recently sold kr2.8m worth of stock

VP & Head of Research exercised options to buy kr1.2m worth of stock.

BioArctic AB (publ) Receives Patent in Japan for New Antibodies Targeting Parkinson's Disease

Consensus revenue estimates increase by 13%

BioArctic AB (publ) (STO:BIOA B) Analysts Are Way More Bearish Than They Used To Be

Analysts Have Lowered Expectations For BioArctic AB (publ) (STO:BIOA B) After Its Latest Results

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

New Forecasts: Here's What Analysts Think The Future Holds For BioArctic AB (publ) (STO:BIOA B)

Consensus revenue estimates increase by 12%

BioArctic AB (publ) to Report Q3, 2024 Results on Nov 14, 2024

Eisai Announces Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Files in South Korea

Vice President of Communications & IR recently sold kr1.7m worth of stock

BioArctic AB (publ) Approves Board Changes

Now 21% undervalued

Eisai Announces Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease

VP & Head of Research recently sold kr6.5m worth of stock

Things Look Grim For BioArctic AB (publ) (STO:BIOA B) After Today's Downgrade

Insider recently bought kr241k worth of stock

First quarter 2023 earnings released

Companies Like BioArctic (STO:BIOA B) Can Afford To Invest In Growth

Independent Director recently sold kr3.3m worth of stock

Price target increased by 12% to kr400

BioArctic AB (publ) Announces Board Changes

Full year 2022 earnings released: kr0.13 loss per share (vs kr1.36 loss in FY 2021)